Despite achieving complete remission after intensive therapy, most patients with cytogenetically normal (CN) AML relapse due to the persistence of submicroscopic residual disease. In this pilot study, we hypothesized that detection of leukemia-specific mutations following consolidation treatment using a targeted parallel sequencing approach predicts relapse. We included 34 AML patients of whom diagnostic material and remission bone marrow slides after at least one cycle of consolidation were available. Isolated DNA was screened for mutations in 19 genes using an Ion Torrent sequencing platform. Furthermore, the variant allelic frequency of distinct mutations was validated by digital PCR and sequencing using a barcoding approach. Twenty-seven out of 34 patients could be analyzed for mutation clearance. We identified 68 somatic mutations at diagnosis (median, 3 mutations per patient; range 1-5) and 22 of these were still detected in 16 patients after consolidation therapy with a reliable sensitivity of 0.5% (median, 1 mutation; range 0-3). The most frequent noncleared mutations were found in DNMT3A. However, as persistence of these mutations has recently been shown to be without any impact on relapse risk, we performed survival and relapse risk analysis excluding DNMT3A mutations. Importantly, persistence of non-DNMT3A mutations was associated with a higher risk of AML relapse (7/8 pts versus 6/19 pts; P 5 .013) and with a shorter relapse-free survival (333 days vs. not reached; log-rank P 5 .0219). Detection of residual disease by routine targeted parallel sequencing proved feasible and effective as persistence of somatic mutations other than DNMT3A were prognostic for relapse in CN AML.
patients of whom diagnostic material and remission bone marrow slides after at least one cycle of consolidation were available. Isolated DNA was screened for mutations in 19 genes using an Ion Torrent sequencing platform. Furthermore, the variant allelic frequency of distinct mutations was validated by digital PCR and sequencing using a barcoding approach. Twenty-seven out of 34 patients could be analyzed for mutation clearance. We identified 68 somatic mutations at diagnosis (median, 3 mutations per patient; range 1-5) and 22 of these were still detected in 16 patients after consolidation therapy with a reliable sensitivity of 0.5% (median, 1 mutation; range 0-3). The most frequent noncleared mutations were found in DNMT3A. However, as persistence of these mutations has recently been shown to be without any impact on relapse risk, we performed survival and relapse risk analysis excluding DNMT3A mutations. Importantly, persistence of non-DNMT3A mutations was associated with a higher risk of AML relapse (7/8 pts versus 6/19 pts; P 5 .013) and with a shorter relapse-free survival (333 days vs. not reached; log-rank P 5 .0219). Detection of residual disease by routine targeted parallel sequencing proved feasible and effective as persistence of somatic mutations other than DNMT3A were prognostic for relapse in CN AML.
| I N TR ODU C TI ON
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and, despite considerable progress in understanding the pathogenesis of the disease, its outcome is still adverse in many patients. [1] [2] [3] The main reason of this unfavorable prognosis is the high frequency of relapse due to persistence of trace amounts of chemoresistant leukemic cells after therapy. 4, 5 Currently, the intensity of treatment, which may also include allogeneic hematopoietic stem cell transplantation, is based on risk stratification of patients at diagnosis.
Specific chromosomal and molecular aberrations assign patients into three risk groups in the current European Leukemia Net (ELN) guidelines. 6 While high risk patients should undergo allogeneic stem cell transplantation (SCT), intermediate-dose cytarabine consolidation is the treatment of choice after induction therapy in good risk patients.
However, up to 60% of AML patients cannot be assigned to one of these two groups and are therefore categorized into the intermediate risk group (IR) . The majority of these patients has a normal karyotype and clinical outcome as well as relapse risk vary considerably within this group. 3, 5, [7] [8] [9] [10] Genomic approaches have identified recurrent somatic mutations in a limited number of genes in the vast majority of AML patients. 3, [11] [12] [13] Besides increasing evidence that some of these mutations are associated with outcome, [14] [15] [16] [17] a recent study has shown that investigational genomic approaches detecting these mutations after induction chemotherapy can also be used to assess the clearance In this pilot study, we determined whether a broadly available predesigned targeted sequencing approach encompassing nineteen recurrently mutated genes for mutational analysis at AML diagnosis can also be reliably used to assess the clearance of leukemia-associated mutations in patients with cytogenetically normal AML. In contrast to the study of Klco et al., 18 we focused on remission samples obtained after at least one consolidation therapy and asked whether this approach is feasible throughout therapy using easily available remission material, such as DNA isolated from bone marrow slides, and whether persistent molecular disease is associated with less-favorable clinical outcomes.
| M E TH ODS

| Patients
Thirty-four patients with cytogenetically normal AML, who had achieved complete remission after induction chemotherapy and had received at least one consolidation therapy, were included in this retrospective study. Diagnosis and risk stratification of AML was made according to the ELN guidelines published in 2010. 19 Accordingly, in addition to cytogenetics, mutational analysis of the genes NPM1, FLT3,
and CEBPA was performed in all patients. All patients gave written informed consent and the study was approved by the institutional review board of the Medical University of Graz, Austria (26-050 ex 13/14).
| Ion torrent targeted deep sequencing
Targeted deep sequencing of diagnostic AML sample was done as described previously. 20 In brief, using at least 20 ng DNA isolated from frozen or fresh diagnostic bone marrow or peripheral blood, the entire To determine the analytic sensitivity of the assay, dilution series including six known mutations were performed. In all cases, a variant allelic frequency (VAF) of 0.5% was reliably detected (see Supporting Information Figure S1a ). In addition we calculated the error rate, i.e. false positive variant calls, to assess the specificity.
For sequencing of remission material after at least one consolidation therapy DNA was extracted from BM slides using the QIAamp DNA Micro Kit and DNA concentrations were determined using Qubit dsDNA BR Assay Kits (Life Technologies). Due to lower amounts of DNA obtained from the remission samples after consolidation therapy an average of 15.6 ng DNA (1.0-92.2 ng) was used for these samples.
Sequencing was performed in duplicates as described above for diagnostic material.
| High resolution mutation analysis of DNMT3A and NPM1 hotspot mutations
The NPM1 hotspot mutation c.863_864insTCTG, p.W288fs was analyzed using digital PCR (dPCR) performed on the QuantStudio 3D platform (Life Technologies). A TaqMan assay specific for the detection of the mutation was designed using the Custom TaqMan ® Assay
Design Tool (Thermo Fisher). Specificity of the assays was tested according to the manufacturer's recommendations and the analytical sensitivity was determined using a serial dilution of a sample with known mutated fraction in the background of a normal control DNA (Promega) (see Supporting Information Figure S1b ). For dPCR the total amount of input DNA of diagnostic samples was 120 ng. Due to limited availability of DNA from the remission samples after consolidation therapy an average of 18 ng DNA (0.8-60 ng) was used for these samples. All samples were run in duplicates using Digital PCR 20k Chips and a QuantStudio 3D instrument (Life Technologies). Raw data were analyzed using the relative quantification module of the QuantStudio 3D Analysis Suite Software including a Poisson correction. The confidence level was set to 95% and the desired precision value was 10%.
Mutant allele frequencies of other mutations in NPM1 as well as the hotspot mutation c.2645G > A, p.R882H in DNMT3A were assessed using the Safe-SeqS method. 25 Primers were designed using Illumina specific adapters were attached and after purification, PCR fragments were run on an Agilent Bioanalyzer DNA 7500 chip (Agilent Technologies) for quality control and quantification. All samples from one patient were pooled equimolarily and sequenced on an Illumina
MiSeq in a 2 3 150 bp paired-end run. Generated reads were grouped to read families according to the UID, which ideally was derived from the same PCR template. However, since sequencing errors can affect the UMI sequence this might lead to an overestimation of unique molecules. After grouping, a consensus sequence of each read family was generated by picking a base that occurs in at least 80% of all the reads assigned to a family at that position. Forward and reverse sequences were merged using FLASH 26 and the resulting FastQ file was aligned to the human reference genome (hg19) using BWA 27 and samtools. 28 Alignments were visualized in IGV 23 in order to detect variations.
| Statistical analysis
Differences in characteristics of patients were calculated using a twosided Fisher's exact or Mann-Whitney tests. Comparison between groups concerning VAF or sequencing depth of distinct amplicons was also done using the Mann-Whitney test. The Kaplan-Meier method was applied to generate the survival curves and differences were assessed by Log-Rank analysis. Cox regression was used for multivariate survival analysis. All statistical analyses were carried out using GraphPad Prism software version 7.0 (GraphPad Software, La Jolla, CA, USA) and R 3.4.0 (www.r-project.org). Lin's concordance correlation coefficient between different technical approaches was calculated using the epi.ccc function in the epiR package. Moreover, a bias correction factor that measures (C.b) how far the best-fit line deviates from a line at 45 degrees through the origin was calculated. All hypothesis testing was carried out for alpha 5 0.05.
| R E SU LTS
Thirty-four patients with AML and normal karyotype were included in this study and referred to parallel sequencing of diagnostic material. In three cases no informative mutation could be identified, either because no mutation was found (two cases) or the somatic nature of the mutation could not unequivocally be determined (one case; the experimental flow-chart is given in Supporting Information Figure S2 ). Of the remaining 31 patients bone marrow slides were available after consolidation, but one was excluded due to low cell counts rather reflecting blood than bone marrow. In three cases the amount of DNA isolated from bone marrow slides was not sufficient for parallel sequencing using the Table 1 .
With an average reading depth of 6547x per amplicon indicating adequate sequencing of samples, 68 somatic mutations were identified at diagnosis in these 27 patients (median number of mutations per patient: 3, range 1-5). In accordance to the published literature the most commonly affected genes were DNMT3A and NPM1, followed by TET2 and CEBPA (see Supporting Information Figure S3 ). Before we analyzed DNA from material obtained after consolidation, we deter- Table S1 (see Supporting Information Table S1 ). Applying a z-score of 3, the mean cut-off for a reliable variant calling was 0.28%, with IDH2 p.R140Q and CEBPA p.
T310A being the only exceptions with a cut-off >0.5% which is consistent with the assessed analytical sensitivity from the dilution series.
When calculating a hypothetical misclassification rate for mean cut-off of 0.28% for 100 patients with e.g. IDH1 R132G at exactly 0.5% with a 10.0003 depth, we would not miss a single patient since the expected VAFs according to a Poisson distribution would range between 0.33% and 0.7%. However, setting the cut-off to 0.5% would lead to a false negative rate of 20%.
From these data and calculations we concluded that with this approach we were able to detect one cell carrying a heterozygous mutation among 99 normal bone marrow cells and therefore defined persistent residual disease as a detected VAF of >0.5% with sufficient sensitivity and specificity.
By applying this cut-off, 22 of the initial 68 mutations (32.4%) were still detected in 16 patients (59.3%) after at least one consolidation GAKSCH ET AL.
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therapy (median one mutation per patient, range 0-3; see Figure 1A ).
Changes of the VAF in the most commonly affected genes are shown in Table S1 for selected amplicons). Accordingly, cut-off values based on a z-score of 3 obtained from remission materials were comparable to the ones from diagnostic material (see Supporting Information Table S1 ).
Together these data indicate that sequencing data from DNA isolated from bone marrow slides were of sufficient quality.
In order to validate the results for the two most commonly mutated genes obtained by the Ion Torrent sequencing we used the high-resolution methods digital PCR for the NPM1 mutation p.W288fs
and Safe-SeqS for other NPM1 mutations and p.R882H mutation in Although DNMT3A mutations have been related to chemoresistance and thus may cause adverse outcome, 31 they have been shown to predominantly occur in preleukemic stem cells, which expand after therapy and contribute to a major extent to the regenerating bone marrow. 32, 33 Accordingly, persistence of DNMT3A mutations has recently been shown to be without any impact on relapse risk. 34, 35 Therefore, we performed survival and relapse risk analysis excluding DNMT3A mutations (for persistence of non-DNMT3A mutations in patients see also Figure 1B ). Importantly, persistence of non-DNMT3A mutations was significantly associated with a higher risk of AML relapse (7 out of 8 pts versus 6/19 pts; P 5 .013, see Figure 1B ) and with a shorter relapse-free survival (333 days vs. not defined; log-rank P 5 .0236; see Figure 3A ). In addition, there was a trend for worse overall survival (log-rank P 5 .0502; see Figure 3B ). In multivariate analysis including age, leucocyte counts and genetic risk (good vs. intermediate-1 according to ELN criteria 2010) residual disease positivity as defined by persistence of non-DNMT3A mutations with a VAF >0.5% remained statistically significant as an adverse factor for relapse-free survival (P 5 .031; hazard ratio for relapse 2.16 (95% confidence interval 1.38-3.97)).
| D ISC USSION
In this pilot study we used parallel sequencing with an Ion Torrent platform and a commercially available predesigned targeted gene panel to determine the clearance of leukemia-associated mutations on remission samples obtained after at least one consolidation therapy in de novo AML patients with normal karyotype. Monitoring by this method proved to be feasible and effective as persistence of non-DNMT3A mutations were prognostic for relapse risk. Therapy: Induction (number of cycles)
.59
a Five patients received an allogeneic stem cell transplantation as part of their consolidation therapy before residual disease testing (one in the relapse and four in the relapse-free group, respectively).
The mutation frequency found with our targeted approach encompassing 19 genes corresponded to what has been previously reported [11] [12] [13] and allowed identification of a somatic mutation suitable for residual disease detection in 31 out of 34 patients (91.2%). Additional sequencing of other recurrently mutated genes might not only increase the number of patients with a trackable mutation but also the number of mutations per patient suitable for residual disease detection.
The latter is of increasing importance, since several recent studies have reported the existence of recurrent mutations in AML not only in leukemic cells but also in hematopoietic stem cells (HSC) and in differentiated hematopoietic cells of several lineages, thus constituting preleukemic mutations. 32, 33 In our study, we found that DNMT3A
mutations recurrently persisted at high VAF as compared to all other mutations indicating that DNMT3 mutations indeed had occurred in preleukemic HSC in these patients. In contrast, all but one TET2 mutations identified in our patients showed markedly decreased VAF levels in remission samples rather excluding the possibility that these mutations had occurred in preleukemic HSC. Based on our own and other findings 34, 35 we thus excluded DNMT3A mutations as marker for residual disease in the analysis. However, further prospective and more comprehensive studies are needed to clearly define which mutational markers are best suited for detection of residual leukemic cells to identify patients with an increased risk of relapse. A combination of mutations may probably be best informative in this situation.
In contrast to methods based on flow cytometry, residual disease detection using parallel sequencing usually does not allow a quality control about the material used for analysis. For example, it was shown that in some aspirates depending on the volume the amount of detected residual disease was significantly reduced due to dilution of the bone marrow with blood. 36 With our approach using DNA isolated from slides we could ensure that the analyzed DNA was indeed derived from bone marrow cells and therefore could circumvent this potential pitfall. Interestingly, although the amount of input DNA was lower in the remission material, uniformity of the amplicon coverage was comparable between diagnostic and remission material suggesting that in the majority of cases DNA isolated from BM slides is sufficient for targeted parallel sequencing.
In AML patients with cytogenetic aberrations (about 50% of all patients), persistence of clonal cytogenetic markers in remission samples has shown an increased risk of relapse. 37, 38 Interestingly, Klco et al.
reported that the clearance of AML-associated mutations as detected by a NGS approach was more sensitive as cytogenetic analysis: while all five patients with residual cytogenetic findings also had nonclearance of mutations, five out of eight patients without cytogenetic findings had Number of all identified somatic gene mutations excluding DNMT3A per patient at diagnosis (light grey) and after consolidation (dark grey) persistent mutations, suggesting that both methods are correlating well but that parallel sequencing is more sensitive. 18 Our data extend these findings to patients with cytogenetically normal AML. Using our approach a marker for residual disease detection could be successfully identified and applied in almost 80% of such patients (27 out of 34). In our study we used digital PCR to validate the results of parallel or VAF < 1% was comparably prognostic concerning event-free and overall survival. 18 However, as expected, with the lower VAF cut-off median survival was longer in both groups when compared to the survival times of groups separated by a VAF of 2.5%. A comparable definition of mutation clearance was used by Kohlmann and colleagues by analyzing the role of persistent RUNX1 mutations in AML patients. 40 Good responders were classified by a VAF <3.61% at first follow-up and had a significantly better event-free and overall survival as poor responders displaying a VAF >3.61%. With our approach of detecting a VAF of 0.5% after at least one consolidation therapy we were able to identify 7 out of 13 (53.8%) patients who relapsed and only one patients with a VAF > 0.5% stayed in complete remission. However, when we used a discriminatory VAF of 5% or 2.5%, as was chosen by Klco et al., 18 MRD positivity was not informative anymore in our cohort (P 5 .40 and P 5 .51, respectively). An explanation for this discrepancy to the data of Klco et al. could be that the time of MRD assessment was different in our study: while Klco assessed MRD levels after induction therapy, we assessed MRD levels after at least one consolidation cycle, meaning that our patients received additional consolidation after they had been in clinical CR. Thus, it is tempting to speculate that with additional treatment only lower MRD levels are informative concerning RFS. In a comprehensive analysis of patients with mutated NPM1 and serial measurements of minimal residual disease using RT-PCR for detection of mutant NPM1 Ivey and colleagues
showed that results obtained from peripheral blood after the second cycle of chemotherapy were most informative concerning overall survival. 41, 42 All these data indicate that different thresholds defining mutation clearance at different time points during therapy may be needed for early and reliable identification of patients at increased risk for relapse. One could envision that in the future distinct thresholds of mutation clearances will define persisting residual disease during the various phases of therapy and therefore establish the requirement for an optimal response to therapy in AML. 
